Protein Drugs Market Size, Share, Trends, Growth Outlook

Global Protein Drugs Market Size is forecast to register a growth rate (CAGR) of 6.6% between 2024 and 2032.

The global Protein Drugs Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Type (Monoclonal Antibodies, Peptide Hormones, Fusion Proteins, Interferons, Others), By Application (Oncology, Autoimmune Disorders, Infectious Diseases, Neurology, Cardiovascular Disorders, Others), By End-User (Hospitals and Clinics, Research Institutes and Academic Centers).

An Introduction to Protein Drugs Market in 2024

The Protein Drugs Market is poised for significant growth, driven by advancements in biotechnology, increasing prevalence of chronic diseases, and the rise of personalized medicine. Protein drugs, including monoclonal antibodies, hormones, and vaccines, are crucial in treating various conditions such as cancer, autoimmune disorders, and infectious diseases. With the growing focus on biologics and biosimilars, pharmaceutical companies are expanding their portfolios to include more protein-based therapies. Innovations in recombinant DNA technology and protein engineering are enhancing the efficacy and specificity of these drugs, leading to better patient outcomes. Additionally, the increasing adoption of targeted therapies, especially in oncology and rare diseases, is further fueling market growth. However, challenges such as high development costs, stringent regulatory requirements, and the complexity of manufacturing protein drugs may slow down the market's expansion. Despite these hurdles, the growing demand for biologics and the continued push for innovation in drug development ensure a positive market outlook.

TABLE OF CONTENTS

1 Introduction to 2024 Protein Drugs Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Protein Drugs Market Size Outlook, $ Million, 2021 to 2032
3.2 Protein Drugs Market Outlook by Type, $ Million, 2021 to 2032
3.3 Protein Drugs Market Outlook by Product, $ Million, 2021 to 2032
3.4 Protein Drugs Market Outlook by Application, $ Million, 2021 to 2032
3.5 Protein Drugs Market Outlook by Key Countries, $ Million, 2021 to 2032

4 Market Dynamics
4.1 Key Driving Forces of Protein Drugs Industry
4.2 Key Market Trends in Protein Drugs Industry
4.3 Potential Opportunities in Protein Drugs Industry
4.4 Key Challenges in Protein Drugs Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Protein Drugs Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Protein Drugs Market Outlook by Segments
7.1 Protein Drugs Market Outlook by Segments, $ Million, 2021- 2032
By Type
Monoclonal Antibodies
Peptide Hormones
Fusion Proteins
Interferons
Others
By Application
Oncology
Autoimmune Disorders
Infectious Diseases
Neurology
Cardiovascular Disorders
Others
By End-User
Hospitals and Clinics
Research Institutes and Academic Centers

8 North America Protein Drugs Market Analysis and Outlook To 2032
8.1 Introduction to North America Protein Drugs Markets in 2024
8.2 North America Protein Drugs Market Size Outlook by Country, 2021-2032
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Protein Drugs Market size Outlook by Segments, 2021-2032
By Type
Monoclonal Antibodies
Peptide Hormones
Fusion Proteins
Interferons
Others
By Application
Oncology
Autoimmune Disorders
Infectious Diseases
Neurology
Cardiovascular Disorders
Others
By End-User
Hospitals and Clinics
Research Institutes and Academic Centers

9 Europe Protein Drugs Market Analysis and Outlook To 2032
9.1 Introduction to Europe Protein Drugs Markets in 2024
9.2 Europe Protein Drugs Market Size Outlook by Country, 2021-2032
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Protein Drugs Market Size Outlook by Segments, 2021-2032
By Type
Monoclonal Antibodies
Peptide Hormones
Fusion Proteins
Interferons
Others
By Application
Oncology
Autoimmune Disorders
Infectious Diseases
Neurology
Cardiovascular Disorders
Others
By End-User
Hospitals and Clinics
Research Institutes and Academic Centers

10 Asia Pacific Protein Drugs Market Analysis and Outlook To 2032
10.1 Introduction to Asia Pacific Protein Drugs Markets in 2024
10.2 Asia Pacific Protein Drugs Market Size Outlook by Country, 2021-2032
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Protein Drugs Market size Outlook by Segments, 2021-2032
By Type
Monoclonal Antibodies
Peptide Hormones
Fusion Proteins
Interferons
Others
By Application
Oncology
Autoimmune Disorders
Infectious Diseases
Neurology
Cardiovascular Disorders
Others
By End-User
Hospitals and Clinics
Research Institutes and Academic Centers

11 South America Protein Drugs Market Analysis and Outlook To 2032
11.1 Introduction to South America Protein Drugs Markets in 2024
11.2 South America Protein Drugs Market Size Outlook by Country, 2021-2032
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Protein Drugs Market size Outlook by Segments, 2021-2032
By Type
Monoclonal Antibodies
Peptide Hormones
Fusion Proteins
Interferons
Others
By Application
Oncology
Autoimmune Disorders
Infectious Diseases
Neurology
Cardiovascular Disorders
Others
By End-User
Hospitals and Clinics
Research Institutes and Academic Centers

12 Middle East and Africa Protein Drugs Market Analysis and Outlook To 2032
12.1 Introduction to Middle East and Africa Protein Drugs Markets in 2024
12.2 Middle East and Africa Protein Drugs Market Size Outlook by Country, 2021-2032
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Protein Drugs Market size Outlook by Segments, 2021-2032
By Type
Monoclonal Antibodies
Peptide Hormones
Fusion Proteins
Interferons
Others
By Application
Oncology
Autoimmune Disorders
Infectious Diseases
Neurology
Cardiovascular Disorders
Others
By End-User
Hospitals and Clinics
Research Institutes and Academic Centers

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
AbbVie Inc
Amgen Inc
AstraZeneca PLC
Biogen Inc
Bristol-Myers Squibb Company
Eli Lilly and Company
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Pfizer Inc
Roche Holding AG
Sanofi

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Monoclonal Antibodies
Peptide Hormones
Fusion Proteins
Interferons
Others
By Application
Oncology
Autoimmune Disorders
Infectious Diseases
Neurology
Cardiovascular Disorders
Others
By End-User
Hospitals and Clinics
Research Institutes and Academic Centers